Literature DB >> 27829276

Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency.

Vitor Werneck Krauss Silva1, Gokce Askan1, Tanisha D Daniel1, Maeve Lowery2, David S Klimstra3, Ghassan K Abou-Alfa3, Jinru Shia4.   

Abstract

The pathology of biliary carcinomas is diverse with different gross and histological features in tumors arising in the different segments of the biliary system. Various epidemiological risk factors, varied genetic makeup, and tissue microenvironment are contributory factors. As biliary tumors have been shown to be a part of the Lynch syndrome tumor spectrum, it is plausible to speculate that DNA mismatch repair (MMR) deficiency plays a role in biliary tumors. Literature data suggest that DNA MMR deficiency indeed occurs in these tumors, albeit infrequently with the reported frequencies (weighted for sample size) of high level microsatellite instability (MSI) being 5% each for gallbladder carcinoma and carcinoma of extra-hepatic bile ducts, and 10% each for intrahepatic cholangiocarcinoma and ampullary carcinoma. Importantly, the presence of MMR deficiency in these tumors has been shown to have different implications with regard to its association with Lynch syndrome, tumor histological features, and other clinical characteristics, when compared with non-biliary tumors or among the biliary tumors from the different segments of the biliary system. Ongoing and future efforts that utilize large scale sequencing techniques and aim at detecting actionable molecular targets should emphasize a multidisciplinary approach that integrates genomic discoveries with not only functional studies but also studies of tumor pathology and the tumor's clinical and biological behavior.

Entities:  

Keywords:  Microsatellite instability (MSI); ampulla; bile duct; biliary neoplasm; cholangiocarcinoma; gallbladder

Mesh:

Year:  2016        PMID: 27829276     DOI: 10.21037/cco.2016.10.04

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


  49 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Authors:  Maeve A Lowery; Ryan Ptashkin; Emmet Jordan; Michael F Berger; Ahmet Zehir; Marinela Capanu; Nancy E Kemeny; Eileen M O'Reilly; Imane El-Dika; William R Jarnagin; James J Harding; Michael I D'Angelica; Andrea Cercek; Jaclyn F Hechtman; David B Solit; Nikolaus Schultz; David M Hyman; David S Klimstra; Leonard B Saltz; Ghassan K Abou-Alfa
Journal:  Clin Cancer Res       Date:  2018-05-30       Impact factor: 12.531

Review 3.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

4.  Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Biliary Tract Cancers Associated with Lynch Syndrome.

Authors:  Jordan M Cloyd; Yun Shin Chun; Naruhiko Ikoma; Jean Nicolas Vauthey; Tlhomas A Aloia; Amanda Cuddy; Miguel A Rodriguez-Bigas; Y Nancy You
Journal:  J Gastrointest Cancer       Date:  2018-03

Review 5.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

Review 6.  Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer.

Authors:  Lukas Perkhofer; Alica K Beutel; Thomas J Ettrich
Journal:  Visc Med       Date:  2019-02-07

Review 7.  Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.

Authors:  Avani Athauda; Caroline Fong; David K Lau; Milind Javle; Ghassan K Abou-Alfa; Chigusa Morizane; Keith Steward; Ian Chau
Journal:  Cancer Treat Rev       Date:  2020-03-12       Impact factor: 12.111

8.  A real-world study of the efficacy and safety of anti-programmed cell death-1 therapy combined with chemotherapy or targeted therapy in patients with advanced biliary tract cancer.

Authors:  Danyang Sun; Junxun Ma; Jinliang Wang; Lijie Wang; Sujie Zhang; Guangying Chen; Xiaoyan Li; Pengfei Cui; Xuan Zheng; Yi Hu
Journal:  J Gastrointest Oncol       Date:  2020-12

Review 9.  Management of Intrahepatic Cholangiocarcinoma.

Authors:  Sudha Kodali; Akshay Shetty; Soumya Shekhar; David W Victor; Rafik M Ghobrial
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

10.  Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy.

Authors:  Jing Yu; Xi Zhang; Qiyue Huang; Sirui Tan; Xianze Xiong; Hongfeng Gou
Journal:  Cancer Manag Res       Date:  2021-05-31       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.